IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis by Young-Mee Moon et al.
RESEARCH ARTICLE Open Access
IL-32 and IL-17 interact and have the potential to
aggravate osteoclastogenesis in rheumatoid
arthritis
Young-Mee Moon1†, Bo-Young Yoon2†, Yang-Mi Her1, Hye-Joa Oh1, Jae-Seon Lee1, Kyoung-Woon Kim3,
Seon-Yeong Lee1, Yun-Ju Woo1, Kyung-Su Park1, Sung-Hwan Park1, Ho-Youn Kim1 and Mi-La Cho1*
Abstract
Introduction: Interleukin (IL)-32 and IL-17 play critical roles in pro-inflammatory responses and are highly
expressed in the synovium of patients with rheumatoid arthritis (RA). We investigated the relations between these
two cytokines (IL-17 and IL-32) for their ability to induce each other and to stimulate osteoclasts in RA fibroblast-
like synoviocytes (FLSs) and T cells.
Methods: FLSs were isolated through surgical synovectomy obtained from patients with RA or osteoarthritis (OA).
Real-time PCR were performed to evaluate the expression of IL-32, IL-17 and osteoclast-related genes.
Immunohistochemical staining and tartrate-resistant acid phosphatase (TRAP) staining were performed to
determine the distribution of inflammatory cytokines and the presence of osteoclastogenesis.
Results: IL-17 induced the expression of IL-32 in the FLSs from RA patients, as assessed by microarray. IL-32
production was increased by IL-17. IL-32 in the FLSs from RA patients induced the production of IL-17 in CD4+
T cells. IL-32 and IL-17 were colocalized near TRAP-positive areas in joint specimens. IL-17 and IL-32 synergistically
induced the differentiation of osteoclasts, as demonstrated by the expression of osteoclast-related genes. IL-32 and
IL-17 also could induce resorption by osteoclasts in a RANKL-dependent manner.
Conclusions: IL-17 affected the expression of IL-32 in FLSs of RA patients and IL-32 induced the production of
IL-17 in CD4+ T cells. Both IL-17 and IL-32 cytokines can reciprocally influence each other’s production and amplify
the function of osteoclastogenesis in the in RA synovium. Separately, IL-17 and IL-32 each stimulated
osteoclastogenesis without RANKL. Together, the two cytokines synergistically amplified the differentiation of
osteoclasts, independent of RANKL stimulation.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoim-
mune disease that predominantly affects multiple peripheral
synovial joints. The synovial environment has numerous
inflammatory cells such as T cells, B cells, fibroblast-like
synoviocytes (FLSs) and antigen-presenting cells, which can
cause the development of RA. FLSs constitute the synovial
lining cells that have a key role in pannus formation and
destruction of joints [1]. In addition, numerous cytokines
have been implicated in the immune processes that are
associated with RA. T cells, the most invading type of lym-
phocyte in the RA synovium, can contact and activate FLSs
[2,3]. A variety of in vitro and in vivo models have shown
that TNF-dependent networks are involved in critical
pathogenic interactions in RA synovitis. In recent years,
new novel cytokines such as IL-17 and IL-32 have been
reported to be involved in the pathogenesis or regulation of
synovial inflammation.
IL-17, a proinflammatory cytokine produced by T helper
(Th)17 cells [4], plays a key role in the propagation of joint
inflammation, cartilage destruction and bone erosion[5,6],
and it is present in both the synovium and synovial fluid
[7]. IL-17 participates in the joint inflammation of RA via
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activation of T cells and FLSs by secreting cytokines and
chemokines such as IL-6, IL-8, 1L-16, stromal cell-derived
factor-1 (SDF-1), matrix metalloproteinase (MMP)-3 and
MMP-1 [8-11]. Moreover, IL-17 is well known as a strong
inducer of osteoclastogenesis [5].
IL-32, a recently discovered cytokine, was originally
described as natural killer (NK) cell transcript 4 (NK4)
[12]. IL-32 has four splice variants, IL-32a, IL-32b, IL-32δ
and IL-32g, with IL-32a as the most abundant transcript,
and IL-32g as the most active isoform. The expression of
TNF-a and IL-6 are significantly correlated with IL-32g
expression [13]. IL-32 is expressed in NK cells, T cells,
epithelial cells and blood monocytes upon stimulation by
inflammatory cytokines such as IL-1b, IL-18, IFN-g and
TNF-a by the phosphatidylinositol 3-kinase/Akt and NF-
B/AP-1 systems [14]. IL-32 is highly expressed in the
synovial tissue and FLSs of RA patients, but not in
osteoarthritis patients [15]. IL-32 can also induce inflam-
matory cytokines and chemokines such as TNF-a, IL-1b,
IL-8 and IL-6 by the activation of NF-B and p38 mito-
gen-activated protein kinase [16]. Injection of human
IL-32 into the knee joints of naïve mice results in joint
swelling, infiltration and cartilage damage. For these rea-
sons, IL-32 has been recognized as a proinflammatory
cytokine, and has been implicated in inflammatory disor-
ders such as RA and inflammatory bowel disease [17,18].
IL-32 and IL-17 are thought to be associated with patho-
genesis, and are frequently mentioned together as they
seem to have similar roles. It was reported that CXC che-
mokine receptor 4 (CXCR4), lamina propria lymphocytes
(LPL) and IL-32 were identified by IL-17A or IL-17F plus
TNFa on RA synoviocytes [19]. Studies using RA FLSs
and CD4+ T cells or dendritic cells have shown a recipro-
cal induction between TNFa and IL-32, creating a TNFa/
IL-32/TNFa-positive autoinflammatory loop [20]. More-
over, IL-32 production is partially dependent on TNFa,
and the treatment of RA patients with anti-TNFa has
resulted in the reduction of IL-32 protein in synovial tis-
sue. In a recent report, it was suggested that IL-32g contri-
butes to the maturation and activation of immature
dendritic cells (DCs) and increases Th1 and Th17
response by IL-12 and IL-6 [21]. In addition, IL-17 and
IL-32 have been shown to influence pathogenesis via the
common protein p300 and DAPK-1, through the TNF-R1
dependent/independent pathway [22].
From these investigations, we hypothesized that IL-32
and IL-17 interact with each other, and function to
amplify inflammatory reactions in RA. In this study, we
examined the interaction between the two cytokines, and
further investigated their synergistic involvement in
osteoclastogenesis functions. Osteoclasts have a key role
in the joint destruction of RA. It was reported that both
IL-17 and IL-32 induce the generation of osteoclasts
[5,23,24]. IL-17 functionally upregulates the receptor
activator of NF-B (RANK) on osteoclast precursors
causing increased sensitivity to RANK ligand (RANKL)
signaling, leading to increased bone destruction [25]. A
recent study showed that IL-32g has a greater potential
for generating osteoclasts compared to IL-17 in the pre-
sence of soluble RANKL [24].
Our results suggest that IL-17 and IL-32 stimulate each
other’s production, and both inflammatory cytokines
synergistically induce osteoclastogenesis. Eventually, IL-17
and IL-32 might accelerate synovial inflammation and




FLS cell lines were prepared from the synovectomized tis-
sue of RA patients who were undergoing joint replacement
surgery [8]. Six- to eight-week-old male DBA/1J mice ()
were maintained for CIA induction. IL-1R antagonist-defi-
cient mice (IL-1Ra-/- mice) in a BALB/c background were
provided by Dr Y Iwakura (University of Tokyo, Tokyo,
Japan). All the experimental procedures were examined
and approved by the Animal Research Ethics Committee
at the Catholic University of Korea.
Cell preparation
Peripheral blood was obtained from healthy donors using
heparin-treated syringes. Peripheral blood mononuclear
cells (PBMCs) were isolated by density centrifugation
using Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden).
Mice splenocytes were isolated through a mesh and the
red blood cells (RBCs) were lysed with 0.83% ammonium
chloride. To purify the CD4+ T cells, the cell suspensions
were incubated with CD4-coated magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany) for 15 minutes at
4°C and the cells were isolated on magnetic-activated cell
sorting (MACS) separation columns (Miltenyi Biotec).
The CD4+ T cells were cultured with the stimuli: recombi-
nant human IL-17, human IL-23, human IL-32a (R&D
systems, Minneapolis, MN, USA), TGF-b (Peprotech,
Rocky Hill, NJ, USA), and membrane-bound anti-CD3
antibody (0.5 μg; BD PharMingen, CA, USA), and the cells
were pretreated with the inhibitors parthenolide (10 μM),
LY294002 (10 μM) (A.G. Scientific, Inc., San Diego, CA,
USA), or an anti-human IL-17 blocking antibody (R&D
systems) for 2 h.
Preparation of an autoimmune arthritis mice model
To induce type ll collagen-induced arthritis (CIA), 0.1 ml
of an emulsion containing 100 μg bovine type II collagen
(CII) and complete Freund’s adjuvant (CFA; Chondrex,
Redmond, WA, USA) was injected intradermally into the
base of the tail as a primary immunization. Two weeks
later, a booster injection of 100 ug CII dissolved and
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emulsified 1:1 with incomplete Freund’s adjuvant (DIFCO,
Detroit, MI, USA) was administered to the hind leg.
RNA preparation and real-time PCR
The total RNA was extracted using TRI Reagent (MRC,
Cincinnati, OH, USA) according to the manufacturer’s
instructions. The RNA concentrations were measured
using a NanoDrop ND-1000 (Thermo Fisher Scientific,
Waltham, MA, USA). Reverse transcription of 2 μg of the
total mRNA was conducted at 42°C using RevertAid™
M-MuLV Reverse Transcriptase and RNase inhibitor
(Fermantas, Burlington, ON, Canada). PCR amplification
of cDNA aliquots was performed by adding SYBR green
mixture (Takara, Shiga, Japan) in a LightCycler (Roche
Diagnostics Mannheim, Germany). The relative expres-
sion levels were calculated by normalizing the targets to
the endogenously expressed housekeeping gene (b-actin).
Melting curve analysis was performed immediately after
the amplification protocol under the following condi-
tions: 0 s (hold time) at 95°C, 15 s at 65°C and 0 s (hold
time) at 95°C. The temperature change rate was 20°C/s
except in the final step, in which it was 0.1°C/s. The
crossing point (Cp) was defined as the maximum of the
second derivative from the fluorescence curve.
Bead array gene expression analysis
Total RNA (200 ng of total RNA) was used as a template
for producing double-stranded cDNA and to perform in
vitro transcription amplification using the Illumina Total
Prep RNA amplification kit (Ambion, TX, USA), following
the manufacturer’s instructions. The biotin-labeled cRNA
(750 ng) was purified and hybridized to the HumanRef-8
BeadChip at 58°C for 16 h by following the Illumina
whole-genome gene expression protocol for BeadStation.
The arrays were scanned with the Illumina BeadArray
Reader. Data normalization was performed using quantile
normalization.
Histology and Immunohistochemistry
Immunohistochemical staining was performed on sections
of the synovium. Briefly, the synovial samples, obtained
from four patients with RA and one patient with OA, were
fixed in 4% paraformaldehyde solution overnight at 4°C,
dehydrated with alcohol, washed, embedded in paraffin
and sectioned into 7-μm-thick slices. The sections were
depleted of endogenous peroxidase activity by adding
methanolic hydrogen peroxide (H2O2) and blocking with
normal serum for 30 minutes. The sections were then
incubated overnight at 4°C with goat anti human IL-17,
anti -IL-32 antibody (R&D Systems), anti -human NF-B
p50 and 65 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and p-IB, p-AKT and AKT (Cell Signaling Tech-
nology, Danvers, MA, USA). A hind leg of each mouse
was fixed with 1% formalin, decalcified in EDTA and
embedded in paraffin wax. The sections were then stained
with H&E and tartrate-resistant acid phosphatase (TRAP)
stain. The tissues were incubated with the primary IL-17
antibody (Santa Cruz Biotechnology) and IL-32 antibody
(Abfrontier, Seoul, South Korea) overnight at 4°C. The
samples were incubated with biotinylated anti-goat IgG
and anti-rabbit IgG secondary antibodies for 20 minutes.
The sections were then incubated with streptavidin-perox-
idase complex (Vector Laboratories Ltd., Peterborough,
UK) for 1 h followed by incubation with 3, 3-diaminoben-
zidine (Dako, Glostrup, Denmark). The sections were
counterstained with hematoxylin and the samples were
photographed using a photomicroscope (Olympus, Tokyo,
Japan).
Osteoclast differentiation and activity
After isolation from whole blood, human PBMCs were
incubated for 3 h. To remove nonadherent cells, the cul-
tures were rinsed in medium. The adherent cells were cul-
tured as osteoclast precursors using recombinant human
macrophage-colony stimulating factor (M-CSF) in mini-
mum essential medium alpha modification (a-MEM; Invi-
trogen, Carlsbad, CA, USA) and 10% heat-inactivated fetal
bovine serum (FBS) for the first 3 days. The osteoclast pre-
cursors were rinsed in medium and stimulated with M-
CSF and RANKL, or IL-17 or IL-32. All the factors were
replenished every 3 days and the cultures were maintained
for up to 21 days. A commercial TRAP kit (Sigma-Aldrich,
St Louis, MO, USA) was used according to the manufac-
turer’s instructions, and cells were counterstained with
hematoxylin. TRAP-positive cells containing three or
more nuclei were scored as osteoclasts. The TRAP-posi-
tive multinucleated cells (MNCs) were counted three
times without the examiner having knowledge of the pre-
viously counted numbers of osteoclasts. To assess osteo-
clast activity, cell culture was performed as described
above with dentine discs (IDS Inc., Boldon, UK) in 96-well
plates. The cells were cultured for 21 days. At day 21 cells
were removed from dentine discs using 10% sodium hypo-
chlorite solution rinsed in distilled water. The dentin discs
were then stained with 50% hematoxylin rinsed in distilled
water. Resorption area was evaluated by light microscopy
and measured using the TMOMRO analysis Ts Lite
Image program (Olympus, Munster, Germany).
Enzyme-linked immunosorbent assay (ELISA)
Antibodies for mouse IL-17 and human IL-17 were
obtained from R&D Systems. The IL-17 concentration
in the culture supernatants was measured by sandwich
ELISA, according to the manufacturer’s instructions. A
standard curve was drawn by plotting the optical density
versus the log of the concentration of IL-17.
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Flow cytometry analysis
Cells were stimulated for 4 h with phorbol 12-myristate
13-acetate and ionomycin. The cells were permeabilized
using a cytoperm/cytofix kit (BD PharMingen) For surface
staining, 5 × 105 cells were washed twice with PBS and
stained with peridinin chlorophyll protein-cyanine 7.7-
conjugated anti-human or mouse CD4 (BD PharMingen)
for 30 minutes at 4°C. To measure the intracellular IL-17
concentrations, the cells were fixed and stained with fluor-
escein isothiocyanate-conjugated anti-human or anti-
mouse IL-17 monoclonal antibody (BD PharMingen) for
30 minutes at 4°C. Staining for the isotype controls was
performed simultaneously using an isotype control anti-
body (BD PharMingen). The cells were analyzed on a
fluorescence-activated cell sorter (FACS), Calibur (BD).
The events were collected and analyzed with FlowJo soft-
ware (TreeStar, Ashland, OR, USA).
Statistical analysis
The experimental values are presented as means ± SD.
Statistical significance was determined by analysis of var-
iance (ANOVA) with Bonferroni’s post-test correction or
Student’s t-test, using the SPSS program (version 10.0);
P-values < 0.05 were considered statistically significant.
Results
Microarray analysis of IL17A inducible cytokine- and
chemokine-related genes
We utilized a microarray to compare the multiple gene
expression profiles representative of the FLSs from
patients with RA and the IL-17-stimulated FLSs. Table 1
shows the IL-17-inducible cytokine and chemokine
genes in the FLSs from patients with RA. Several inflam-
mation-related genes were highly expressed in the IL-
17-stimulated FLSs from RA patients. Our microarray
results indicated that IL-17A induced IL-32 expression
(4.3-fold) in FLSs of RA patients (Table 1). Therefore,
we examined whether IL-17 and IL-32 have an effect on
each other in the inflammatory environment.
IL-17 induced IL-32 expression via NF-B and PI3kinase in
the FLSs of patients with RA
FLSs obtained from synovial tissue of patients with RA
during surgical synovectomy were stimulated by IL-17,
and the IL-32 mRNA level was measured. The IL-32
mRNA level was increased in a dose-dependent manner
(Figure 1A). The IL-32 mRNA level was decreased by the
PI3K inhibitor LY294002 and the NF-B inhibitor parthe-
nolide, and PI3K and NF-B molecules were associated
with the IL-17-induced IL-32 production (Figure 1B) [13].
A higher level of IL-32 was expressed by IL-17-stimulated
FLSs from patients with RA than from patients with OA.
Similarly, NF-B and PI3K signal molecules were also
more highly expressed in synovium from patients with RA
than from patients with OA (Figure 1C).
In the inflammatory condition of RA synovitis, contact
between T cells and FLSs is an important and necessary
mechanism [26]. Co-incubation of FLSs from RA patients
with CD4+ T cells caused an increase in IL-32 mRNA
levels in FLSs (Figure 2A, left panel) and an increase in
IL-17 levels in the supernatants of co-cultures (Figure 2A,
right panel). When treated with IL-17 blockade antibody
Table 1 Interleukin (IL)-17A-inducible genes as determined by microarray analysis of fibroblast-like synoviocytes
(FLSs) from patients with rheumatoid arthritis (RA)
Accession numbers Full name Symbol Folds increased
NM_000584.2 interleukin 8 IL8 509.5
NM_004591.1 chemokine (C-C motif) ligand 20 CCL20 382.0
NM_002993.2 chemokine (C-X-C motif) ligand 6 CXCL6 314.1
NM_000600.1 interleukin 6 IL6 120.6
NM_001511.1 chemokine (C-X-C motif) ligand 1 CXCL1 88.6
NM_007115.2 tumor necrosis factor, alpha-induced protein 6 TNFAIP6 21.1
NM_002089.1 chemokine (C-X-C motif) ligand 2 CXCL2 20.4
NM_002982.3 chemokine (C-C motif) ligand 2 CCL2 20.0
NM_005623.2 chemokine (C-C motif) ligand 8 CCL8 17.5
NM_002421.2 matrix metallopeptidase 1 MMP1 16.1
NM_001078.2 vascular cell adhesion molecule 1 VCAM1 15.2
NM_000201.1 intercellular adhesion molecule 1 ICAM1 9.3
NM_001565.1 chemokine (C-X-C motif) ligand 10 CXCL10 8.2
NM_001012632.1 interleukin 32 IL32 4.3
NM_002006.3 fibroblast growth factor 2 FGF2 2.7
Bead array gene expression analysis of FLSs and IL-17 activated FLSs from patients with RA (RA FLS) at 12 h. After serum starvation for 24 h, the RA FLSs were
stimulated with IL-17A (20 ng/ml) or without IL-17A. Total RNA from RA FLSs was used for the Bead array gene expression analysis. The genes differentially
expressed between the IL-17 activated RA FLSs and the RA FLSs were identified by ANOVA with a P-value < 0.01.
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Figure 1 IL-17 induced expression of interleukin (IL)-32 via NF-B and PI3 kinase in fibroblast-like synoviocytes (FLSs) from patients
with rheumatoid arthritis (RA). (A) FLSs from RA patients (RA FLSs) were cultured with increasing doses (1 and 5 ng/ml) of IL-17 for 12 h.
IL-32 mRNA levels were measured by real-time PCR. ***P < 0.001 (in comparison with nil), ** P < 0.01 (in comparison with nil). (B) RA FLSs were
pretreated with the signal inhibitors parthenolide (10 μM) or LY294002 (10 μM) for 2 h and then cultured with IL-17 (10 ng/ml) for 12 h. The
IL-32 mRNA level was measured by real-time PCR. *P < 0.05 (in comparison with IL-17), **P < 0.01 (in comparison with IL-17). A and B show the
means ± SD of more than three separate experiments. (C) Expression of IL-17, IL-32, phospho-IkB (p-IkB), NF-B (p50), NF-B (p65), phospho-Akt
(p-Akt) and AKT in the synovium of patients with RA or osteoarthritis (OA). Immunostaining was performed using specific antibodies. Data are
representative of three experiments with similar results.
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Figure 2 Interleukin (IL)-17/T helper (Th)17-induced IL-32 expression from rheumatoid arthritis (RA) patients. (A) Production of IL-32 by RA
fibroblast-like synoviocytes (FLSs) in contact with CD4+ T cells. RA FLSs and CD4+ T cells from healthy donors were co-cultured. FLSs (1 × 105) were
cultured with CD4+ T cells (1 × 106) with or without anti-IL-17 blocking antibody (10 μg/ml). IL-17 production was then measured by sandwich
ELISA, and the IL-32 mRNA levels of RA FLSs were determined by real-time PCR. ***P < 0.001 (compared with FLS+CD4+ T cells). (B) Induction of RA
FLS IL-32 production by the supernatant of Th17-polarized cell cultures. RA FLSs and the culture supernatants of Th17-polarized cells from healthy
donors were co-cultured. CD4+ T cells were incubated with membrane-bound anti-CD3 antibody (2 μg/ml), IL-6 (5 ng/ml), IL1b (5 ng/ml), IL-23 (10
ng/ml), TGF-b (5 ng/ml) with or without an anti-IL-17 blocking antibody incubated for 2 h before the next incubation) for 3 days to induce Th17.
polarization. FLS (1 × 105) were cultured with the culture supernatants of these Th17 polarized cells. IL-17 production was measured by sandwich
ELISA and the IL-32 mRNA levels in RA FLSs were determined by real-time PCR. **P < 0.01 (compared with FLSs + culture supernatant of Th17 cells),
*** P < 0.001 (compared with FLSs + culture supernatant of Th17 cells). The data are representative of three experiments with similar results.
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under the same conditions, the IL-32 mRNA levels in the
FLSs were suppressed (Figure 2A, left panel). The IL-17
levels in the supernatant of co-cultures were also markedly
decreased by blocking with anti-IL-17 antibody (Figure 2A,
right panel).
To confirm the role of IL-17 of CD4+ T cells in induc-
tion of IL-32 expression in FLSs, the IL-17-rich superna-
tant from Th17-polarized cells was added to FLSs from
RA patients. The IL-32 mRNA level in the FLSs from RA
patients was increased in the presence of the Th17-polar-
ized cell supernatant, and blocked with IL-17 blockade
antibody (Figure 2B, left panel). Therefore, IL-17 derived
from direct contact between FLSs from RA patients and
CD4+ T cells (Figure 2A), as well as that secreted by
Th17-polarized cells (Figure 2B), can induce IL-32 expres-
sion in FLSs from RA patients. In both cases, IL-32
expression was arrested by IL-17 blockade. These results
demonstrate that IL-17, an important cytokine in RA, has
a direct role in IL-32 expression by the FLSs of RA
patients.
IL-32 induced the production of IL-17 in human CD4+
T cells and differentiation of Th17 cells
Because IL-32 can induce inflammatory cytokines, we next
assessed the IL-17 production by IL-32. To determine
whether IL-32 induces IL-17 production, CD4+ T cells
from human PBMCs were cultured with membrane-
bound anti-CD3 antibody to activate TCRs and the
expression of IL-17 increased when was stimulated with
IL-32 (Figure 3A). CD4+ T cells from healthy donors were
differentiated using anti-CD3, anti-CD28, anti-IL-4, and
anti-IFN-g, antibodies, and IL-1b and IL-6. FACS analysis
showed an increase in IL-17-expressing cells after IL-32
stimulation (Figure 3B). In addition, IL-17 mRNA levels in
human CD4+ T cells were increased by IL-32 stimulation,
and expression of RORgt, a transcription factor for Th17
differentiation, was also increased by IL-32 stimulation
(Figure 3C). Th17 cells might secrete increased IL-17 in
the presence of IL-32. Indeed, recombinant human IL-32
promoted IL-17 production (Figure 3D). These results
suggest that IL-32 production is affected by IL-17 stimula-
tion, and that IL-32 plays a role in both Th17 cell differen-
tiation and IL-17 secretion.
IL-32 induced IL-17 production in autoimmune arthritis
mouse models
IL-17 and IL-32 interact in human FLSs and T cells from
patients with RA. To confirm this interaction in autoim-
mune arthritis mouse models, splenic CD4+ T cells of
type-II collagen-induced mice (CIA) were cultured with
anti-CD3 or anti-CD3 with IL-32a. Increased IL-17 secre-
tion was observed with IL-32 stimulation in this animal
model (Figure 4A). In addition, we examined whether
IL-32-treated Th17 polarized cells secreted more IL-17, in
a manner similar to that observed in the human RA condi-
tion. CD4+ T cells and irradiated CD4- T cells (as antigen
presenting cells) from CIA mice at 5 weeks after immuni-
zation were co-cultured with Th17 polarizing condition
with/without CII/IL-32. A second challenge with antigen
increased CD4+IL-17+ cells (Figure 4B). Moreover, IL-32
induced the secretion of IL-17 (Figure 4C) and increased
the expression of IL-17 mRNA (Figure 4D). These results
show that a second collagen challenge induced IL-17
secretion, and that IL-32 also promoted IL-17 mRNA
expression and cytokine secretion.
Next, we investigated whether IL-17 and IL-32 have a
role in bony erosion in RA mouse models. To correlate the
location of cytokine expression and osteoclastogenesis, the
synovium of both CIA and IL-1Ra knockout (KO) mice
were analyzed for IL-17, IL-32 and TRAP expression, and
stained with H&E (Figure 4E). Damaged bone areas
demonstrated TRAP-positive cells. IL-32 and IL-17 were
co-localized near the TRAP-positive areas between the car-
tilage and tarsal bone of both mouse models (Figure 4E).
Thus, in two RA animal models, IL-32 induced IL-17 pro-
duction, and IL-32 and IL-17 were expressed in areas of
osteoclast differentiation.
IL-17 and IL-32 synergistically induced osteoclastogenesis
Osteoclast precursors were cultured in the presence of
IL-17 and/or IL-32 with M-CSF, a cytokine involved in
the survival and proliferation of osteoclasts. After 15 days
culture, IL-17 or IL-32 induced the formation of multinu-
cleated TRAP positive cells as shown in Figure 5A. The
numbers of IL-17 or IL-32-stimulated TRAP-positive
MNCs were increased compared to those observed with
M-CSF alone. Although RANKL is well known as a cru-
cial factor for osteoclast differentiation, these results
revealed that IL-32 and IL-17 are involved in RANKL-
independent mechanisms of osteoclastogenesis. In addi-
tion, the simultaneous stimulation by IL-17 and IL-32
induced an increased number of multinucleated TRAP-
positive cells (Figure 5B). These findings imply that IL-17
and IL-32 synergistically induced osteoclastogenesis from
osteoclast precursor cells in the absence of a RANKL-
RANK interaction. Osteoclast markers, such as calcitonin
receptor, cathepsin K, TRAP and MMP9 mRNAs, were
increased by IL-17 or IL-32 as much as that observed
with RANKL stimulation (positive control). IL-17 and IL-
32 had a synergistic effect on induction of osteoclast mar-
kers at the mRNA level in a RANKL-independent manner
(Figure 5C). In conditions that included IL-32 and IL-17
without RANKL, resorption pit formation was not
observed. When treated with RANKL, IL-32 and IL-17
synergistically accelerated the osteoclast resorption activ-
ity compared with IL-32 or IL-17 alone (Figure 5D).
These results indicate that IL-32 and IL-17 could syner-
gistically induce osteoclastogenesis independent of
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Figure 3 Interleukin (IL)-32 induces the production of IL-17 in human CD4+ T cells. (A) CD4+ T cells from healthy donor human peripheral blood
mononuclear cells (PBMCs) were cultured with membrane-bound anti-CD3 antibody and with/without recombinant human IL-32 (5 ng/ml) for 3 days.
IL-17 production was measured by sandwich ELISA. **P < 0.01 (compared with anti-CD3). (B) Flow cytometry analysis of the expression of IL-17A by
CD4+ T cells treated with membrane-bound anti-CD3 antibody (0.5 μg/ml) and with/without IL-32 (5 ng/ml) for 3 days. These cells were stained with
anti-CD4-Percp cy7.7 and anti-IL-17-FITC, to determine the percentage of IL-17+ cells in the CD4+ gated population. *** P < 0.001 (compared with anti-
CD3). (C) IL-17 and RORgt mRNA levels were measured by real-time PCR in stimulated CD4+ T cells with a membrane-bound anti-CD3 antibody with/
without IL-32 (5 ng/ml). * P < 0.05 (compared with anti-CD3), *** P < 0.001 (compared with anti-CD3). (D) CD4+ T cells from healthy donors were
cultured with membrane-bound anti-CD3 antibody (0.5 μg/ml), anti-CD28 (1 μg/ml), anti-IL-4 (2 μg/ml), anti-IFN-g (2 μg/ml), IL-1b (20 μg/ml) and IL-6
(20 ng/ml) to induce Th17 polarization, and with/without recombinant human IL-32 (5 ng/ml) for 3 days. *** P < 0.001 (compared with Th17) (A), (B, left
panel) and (D) are representative of three experiments with similar results. (B, right panel) and (C) represent means ± SD of three separate experiments.
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Figure 4 Interleukin (IL)-32 induces IL-17 production in an autoimmune arthritis mouse model. (A) CD4+ T cells were isolated from the
spleens of collagen-induced arthritis (CIA) mice, an autoimmune arthritis model. The cells were cultured with membrane-bound anti-CD3 (0.5
μg/ml) and with/without IL-32 (5 ng/ml) for 3 days. IL-17 production was measured by sandwich ELISA. ** P < 0.01 (compared with anti-CD3).
(B-D) Expression of IL-17A by CD4+ T cells cultured under Th17-polarizing conditions for 3 days: anti-CD3 (0.5 μg/ml), anti-CD28 (1 μg/ml), anti-
IFN-gamma (2 μg/ml), anti-IL-4 (2 μg/ml), anti-IL-2 (2 μg/ml), IL-6 (20 ng/ml), TGF-beta1 (2 ng/ml) with/without IL-32 (5 ng/ml) and/or type ll
collagen with irradiated antigen-presenting cells, and then stimulated for 4 h with PMA and ionomycin, followed by intracellular cytokine
staining. The percentage of IL-17+ cells in the CD4+ gated population (B), *** P < 0.001 (compared with Th17) and cytokine level (C) were
measured by sandwich ELISA, *** P < 0.001 (compared with Th17) and mRNA levels (D) were measured by real-time PCR, * P < 0.05 (compared
with Th17). B-D are representative of three experiment with similar results. (E) Expressions of IL-17, IL-32 and tartrate-resistant acid phosphatase
(TRAP) in the synovium of the CIA and IL-1Ra-knock-out (KO) mice, two autoimmune arthritis mouse models. The results shown are
representative of five experiments with similar results.
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Figure 5 Interleukin (IL)-17 and IL-32 synergistically induce osteoclastogenesis. (A) Tartrate-resistant acid phosphatase (TRAP) staining for
identification of osteoclasts. Osteoclast precursors were cultured in the presence of IL-17 (0.1 ng/ml) or/and IL-32 (5 ng/ml) with macrophage
colony-stimulating factor (M-CSF; 25 ng/ml). The receptor activator of the nuclear factor kappa-B ligand (RANKL; 30 ng/ml)-treated group was the
positive control. The medium and stimulus were changed every 3 days. After 15 days, the cells were stained for TRAP activity. (B) Numbers of
multinucleated TRAP-positive cells per well. TRAP-positive cells containing two or more nuclei were scored as osteoclasts. TRAP-positive cells
were counted three times by blind scoring. *P < 0.05 (compared with M-CSF+IL-32+IL-17), **P < 0.01 (compared with M-CSF+IL-32+IL-17).
(C) The mRNAs of TRAP, Cathepsin K, calcitonin receptor (CTR) and matrix metallopeptidase 9 (MMP9), as osteoclast markers were quantified by
real-time PCR. *P < 0.05 (compared with M-CSF+IL-32+IL-17), **P < 0.01 (compared with M-CSF+IL-32)+IL-17), ***P < 0.001 (compared with M-
CSF+IL-32+IL-17). (D) Formation (left) and percent area (right) of resorption pits by osteoclasts on dentine discs. Cell culture was performed as
described with dentine discs in 96-well plates. The osteoclast precursors were cultured in the presence of IL-17 (1 ng/ml) or IL-32 (5 ng/ml) with
M-CSF (25 ng/ml) and RANKL (30 ng/ml). At day 21, the cells were removed from dentine. Resorption area was evaluated by light microscopy
and measured using the image analysis software. (A), (B) and (D) are representative of two or three experiments with similar results. (C) Means ±
SD of more than three separate experiments.
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RANKL, and could synergistically induce resorption by
osteoclasts in a RANKL-dependent manner.
Discussion
IL-32 is a novel cytokine that has been reported to be
an important player in the innate and adaptive immune
response. Innate immune stimulation by the ligands of
toll-like receptors (TLRs) can induce the expression of
IL-32 in FLSs [27]. Recently, the expression of IL-32
was demonstrated in Mycobacterium tuberculosis infec-
tions, inflammatory bowel disease and influenza A virus
infection, in addition to that in autoimmune disease.
However, more research is required to explain the func-
tion of IL-32 in inflammatory disorders.
The expression and regulation of cytokines involved in
RA pathogenesis have been studied extensively over the
past two decades, which is possibly due to the relative ease
of analyzing the synovium of RA patients. These investiga-
tions have broadened and deepened our understanding of
the roles of several cytokines in RA pathogenesis. Further-
more, some studies, most notably those focusing on
TNFa, IL-1, and IL-6, have shown promising ways to
block the cytokines involved in RA pathogenesis. It is
important to characterize the individual cytokines in rela-
tion to the pathogenesis of RA and understanding the
interaction and cross-talk between these cytokines is criti-
cal. Cytokines can amplify other inflammatory cytokines
and then compensate for this by increasing the production
of pro-inflammatory cytokines. For instance, it has been
shown that IL-32 is a potent inducer of TNF-a [28]. In
addition, TNF-a is a potent inducer of endogenous IL-32
expression, and IL-32 itself prolongs TNF-a production,
thus inducing an important autoinflammatory loop [20].
IL-17 is critical for RA pathogenesis and can induce
increased expression of TNFa [25]. To-date, a direct inter-
action between IL-17 and IL-32 has not been reported,
although one study implied their interaction by determin-
ing that these cytokines have common signal intermedi-
ates, p300 and DAPK-1 [22]. Another study demonstrated
that IL-32g-stimulated DCs could induce a Th17 response
when co-cultured with CD4+ T cells [29], implying that
IL-32 affects IL-17 production independent of TNFa.
In this study, we examined the synergistic expressions of
IL-17 and IL-32 and their possible interactions. Using
microarray analysis, we showed that IL-17 induced gene
expression in the FLSs of patients with RA (Table 1), and
that IL-32 mRNA levels increased in a dose-dependent
manner (Figure 1A). Because IL-32a mRNA expression
depends on the PI3-kinase/NF-B systems in human colo-
nic subepithelial myofibroblasts [30], we investigated
whether IL-17 is also dependent on the NF-B/PI3-kinase
pathways in FLSs. of patients with RA. It was confirmed
that this induction occurred through the NF-B and
PI3kinase pathways by using specific inhibitors to block
these pathways (Figure 1B). IL-32 induction by TNF-a, is
mediated via the Syk/Protein Kinase Cδ/JNK signaling
pathways [31]. The transcription and secretion of pro-
inflammatory and anti-inflammatory cytokines have the
complex signal pathways inside cells.
IL-32 expression in the synovium from patients with
RA than in those with OA was increased (Figure 1C).
The expression of IL-32 in synovium of patients with
RA was also co-localized with IL-17, NF-B, and PI3K.
This result suggests that FLSs from patients with RA
could interact with T cells, especially IL-17-producing
Th17 cells, and direct contact could be important for
this interaction.
We observed that co-culture of FLSs with CD4+ T
cells resulted in production of IL-17, which caused IL-
32 expression in FLSs. This IL-32 induction was par-
tially inhibited by blocking with anti-IL-17 antibodies
(Figure 2A). Coculture of FLSs with the IL-17-rich
supernatant from Th17-polarized cells resulted in a
markedly increased IL-32 production by FLSs from RA
patients. To determine whether IL-17 had a direct effect,
we used the supernatant of the IL-17 blocked Th17
polarized cells. These results suggested that IL-17 is
directly related to IL-32 production with the interaction
of CD4+ T cells and FLSs. Since IL-17 was generally not
produced by FLSs, IL-17 secreted from CD4+ T cells
might induce IL-32 expression in FLSs. IL-17-rich
supernatant induced more IL-32 mRNA expression.
Although these inductions were arrested by anti-IL-17
antibody, IL-17-rich supernatant with anti-IL-17 anti-
body was more reduced in IL-32 mRNA expression
than CD4+T cell with anti-IL-17 antibody. The reason
could be due to the production of other factors than IL-
17 by cell-cell contact. The identification of these factors
would be of interest for future study. It has been
reported that TNFa exhibits potent induction of IL-32
secretion in FLSs of patients with RA. One study
showed that IL-17 is related to IL-32 expression in FLSs
of RA patients [19]. In contrast to our results, this study
reported that both IL-17A and IL-17F induced IL-32 to
only a small extent. In addition, IL-17 attenuated the
IL-32 expression induced by TNFa. IL-17, an important
proinflammatory cytokine, is unlikely to have a para-
doxically negative feedback in the autoinflammatory
loop between IL-32 and TNFa. Therefore, we suggest
that our results, showing that IL-17 amplified IL-32
expression in FLSs of patients with RA, are logically
acceptable.
Human IL-32 recombinant protein has been utilized
in mice [18,29], and so we determined whether IL-32
could induce IL-17 production in an autoimmune
arthritis mouse model. Using ELISA and FACS analysis,
we showed that IL-32 induced high IL-17 expression in
splenic CD4+ T cells of CIA mice. IL-32 induced the
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differentiation of CD4+ T cells of RA model mice to
Th17 cells and promoted IL-17 production. In addition,
immunohistochemistry staining indicated that IL-17, IL-
32 and TRAP were co-localized in the joints of CIA and
IL-1R antagonist-deficient mice. These results suggest
that an interaction between IL-32 and IL-17 exists in
both autoimmune arthritis diseases and animal models,
contributing to accelerated inflammation and bone
destruction.
Next, we revealed that IL-17 and IL-32 have synergistic
roles in osteoclastogenesis. Osteoclasts are multinucleated
cells that are responsible for bone resorption and are
derived from hematopoietic precursor cells that circulate
in the blood. It is currently thought that two critical fac-
tors (M-CSF and RANKL) supplied by osteoblasts are
essential for the differentiation and maturation of osteo-
clast precursors. Moreover, some researchers have
reported that a direct interaction between osteoclast pro-
genitors and osteoblasts is required for IL-17-induced
osteoclastogenesis [5]. IL-17 dose-dependently induced
the expression of osteoclast differentiation factor (ODF)
mRNA in osteoblasts. IL-32 also promotes osteoclast dif-
ferentiation and the expression of several specific markers
of osteoclasts such as NFATc1, OSCAR and cathepsin K
[23]. To determine whether IL-17 and IL-32 have a syner-
gistic effect in osteoclastogenesis, we cultured osteoclast
precursors with IL-17 and/or IL-32. IL-17 and IL-32 accel-
erated osteoclastogenesis compared with IL-17, IL-32 or
RANKL stimulation alone (Figure 5A, B). We also exam-
ined the effect of IL-17 and IL-32 on osteoclast differentia-
tion in the presence of anti-RANKL or anti-OPG
antibodies, and observed that osteoclastogenesis occurred
in a manner that was independent of RANKL or OPG
(data not shown). In addition, we investigated whether IL-
17- and IL-32-stimulated osteoclastogenesis was affected
by TNFa. Although we detected TNFa in the supernatant
of IL-17- and IL-32-stimulated differentiated osteoclasts,
blocking with anti-TNFa showed no effect (data not
shown). Therefore, osteoclastogenesis associated with
IL-17 and IL-32 was not dependent on RANKL or TNFa.
To determine the resorption activity of osteoclasts
induced by IL-32 and Il-17, we performed a resorption pit
assay using dentine slices. When IL-32 and IL-17 were
assayed in the absence of RANKL, no resorption pit for-
mation was observed. Moreover, we confirmed that
RANKL is essential for osteoclast resorption activity.
When treated with RANKL, IL-32 and IL-17 synergisti-
cally accelerated osteoclast resorption activity compared
with IL-32 or IL-17 alone. We deduced that IL-32 and
IL-17 could synergistically induce osteoclastogenesis inde-
pendent of RANKL, and were synergistically involved in
the RANKL-dependent resorption function of osteoclasts.
FLSs and CD4+ T cells are found in close proximity in
synovial joints. We suggested that IL-17 and IL-32
could stimulate the reciprocal production of each other,
and amplify inflammatory reactions. In this model, the
two cytokines synergistically stimulate osteoclastogenesis
independently of RANKL, and might increasingly induce
bony erosion and osteopenia together with RANKL,
thus participating in the inflammation associated with
RA. Therefore, interruption of IL-17 and IL-32 might be
a therapeutic target for treatment of inflammatory
arthritis.
Conclusions
This report is the first to show that IL-17 induces IL-32
cytokine expression through the NF-B and PI3-kinase
signal pathways in FLSs of patients with RA. IL-17 is pro-
duced by Th17 cells that differentiate from CD4+ T cells
in patients with RA. In the joint environment of inflam-
mation, CD4+ T cells and FLSs interact with each other
by direct contact and cytokine secretion, and this interac-
tion amplifies the expression of IL-17 and IL-32. IL-32
induced high levels of IL-17 expression in the splenic
CD4+ T cells of CIA mice. Co-localization of IL-32, IL-17
and TRAP suggested the possibility of their functional
interaction in autoimmune arthritis models. Both IL-17
and IL-32 induce the gene markers CTR, capthepsin K,
TRAP and MMP9, which are all related with osteoclasto-
genesis. IL-17 and IL-32 have a synergistic effect on the
expression of these genes in CD4+ T cells and FLSs.
IL-17 and IL-32 have a reciprocal influence on each
other’s production, and enhance osteoclastogenesis in the
synovium of patients with RA.
Abbreviations
ANOVA: analysis of variance; CIA: collagen-induced arthritis; CII: type II
collagen; Cp: crossing point; DC: dendritic cell; FBS: fetal bovine serum;
ELISA: enzyme-linked immunosorbent assay; FACS: fluorescence-activated cell
sorter; FLS: fibroblast-like synoviocyte; H&E: hematoxylin and eosin; IFN:
interferon; IL: interleukin; M-CSF: macrophage colony-stimulating factor;
MMP: matrix metalloproteinase; MNC: multinucleated cell; NF-κB: nuclear
factor-κB; NK: natural killer; OA: osteoarthritis; PI3K: phosphatidylinositol (PI)-3
kinase; PBMC: peripheral blood mononuclear cell; PCR: polymerase chain
reaction; RA: rheumatoid arthritis; RANKL: receptor activator of nuclear factor
kappa-B ligand; RBC: red blood cell; SDF: stromal cell-derived factor; TCR: T
cell receptor; Th: T helper; TLR: toll-like receptor; TNF: tumor necrosis factor;
TRAP, tartrate-resistant acid phosphatase.
Acknowledgements
This work was supported by the Basic Science Research Program through
the National Research Foundation of Korea (NRF), funded by the Ministry of
Education, Science and Technology (grant number 2009-0081791) and by a
grant of the Korea Health Technology R&D Project, Ministry for Health,
Welfare & Family Affairs, Republic of Korea (grant number A092258).
Author details
1The Rheumatism Research Center, Catholic Research Institute of Medical
Science, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul
137-701, South Korea. 2Department of Internal Medicine Inje University Ilsan
Paik Hospital, Juhwa-ro 170, Ilsanseo-gu, Goyang-si, Gyeonggi-do 411-706,
South Korea. 3Conversant Research Consortium in Immunologic disease,
Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of
Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, South Korea.
Moon et al. Arthritis Research & Therapy 2012, 14:R246
http://arthritis-research.com/content/14/6/R246
Page 12 of 13
Authors’ contributions
YMM, BYY and MLC contributed to the conception and design, acquisition
of data, analysis and interpretation of data, drafting of the article and final
approval of the submitted manuscript. OHJ, KWK, KSP and SHP contributed
to immunohistochemistry and TRAP staining. YJW, SYL, YMH, JSL and HYK
helped with the PCR, FACS and ELISA. YMH contributed cell culture. All
authors approved the final manuscript.
Competing interests
The authors declare that they have no competing interests in relation to this
manuscript.
Received: 20 June 2012 Revised: 30 July 2012
Accepted: 25 October 2012 Published: 13 November 2012
References
1. Bucala R, Ritchlin C, Winchester R, Cerami A: Constitutive production of
inflammatory and mitogenic cytokines by rheumatoid synovial
fibroblasts. J Exp Med 1991, 173:569-574.
2. Van Boxel JA, Paget SA: Predominantly T-cell infiltrate in rheumatoid
synovial membranes. N Engl J Med 1975, 293:517-520.
3. Yamamura Y, Gupta R, Morita Y, He X, Pai R, Endres J, Freiberg A, Chung K,
Fox DA: Effector function of resting T cells: activation of synovial
fibroblasts. J Immunol 2001, 166:2270-2275.
4. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD,
McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell
population that induces autoimmune inflammation. J Exp Med 2005,
201:233-240.
5. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S,
Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial
fluids from patients with rheumatoid arthritis is a potent stimulator of
osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
6. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P,
Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB: IL-17 promotes
bone erosion in murine collagen-induced arthritis through loss of the
receptor activator of NF-kappa B ligand/osteoprotegerin balance.
J Immunol 2003, 170:2655-2662.
7. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R,
Portek IJ: Synovial membrane cytokine expression is predictive of joint
damage progression in rheumatoid arthritis: a two-year prospective
study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131.
8. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, Kim HY: IL-17
induces production of IL-6 and IL-8 in rheumatoid arthritis synovial
fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways.
Arthritis Res Ther 2004, 6:R120-128.
9. Cho ML, Jung YO, Kim KW, Park MK, Oh HJ, Ju JH, Cho YG, Min JK, Kim SI,
Park SH, Kim HY: IL-17 induces the production of IL-16 in rheumatoid
arthritis. Exp Mol Med 2008, 40:237-245.
10. Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, Park SH, Lee SH,
Kim HY: Up-regulation of IL-23p19 expression in rheumatoid arthritis
synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38
MAPK-dependent signalling pathways. Rheumatology (Oxford) 2007,
46:57-64.
11. Agarwal S, Misra R, Aggarwal A: Interleukin 17 levels are increased in
juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts
to produce proinflammatory cytokines and matrix metalloproteinases.
J Rheumatol 2008, 35:515-519.
12. Dahl CA, Schall RP, He HL, Cairns JS: Identification of a novel gene
expressed in activated natural killer cells and T cells. J Immunol 1992,
148:597-603.
13. Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB,
Joosten LA: Inflammation-dependent secretion and splicing of IL-32
{gamma} in rheumatoid arthritis. Proc Natl Acad Sci USA 2011,
108:4962-4967.
14. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S,
Takayanagi A, Shimizu N, Fujiyama Y, Andoh A: Epithelial overexpression
of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol
2007, 149:480-486.
15. Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A,
Decraene C, Fournier C, Chiocchia G: Interleukin-32, CCL2, PF4F1 and
GFD10 are the only cytokine/chemokine genes differentially expressed
by in vitro cultured rheumatoid and osteoarthritis fibroblast-like
synoviocytes. Eur Cytokine Netw 2005, 16:289-292.
16. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E,
Kim JM, Yoon DY, Dinarello CA, Kim SH: IL-32 synergizes with nucleotide
oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6
production through a caspase 1-dependent mechanism. Proc Natl Acad
Sci USA 2005, 102:16309-16314.
17. Dinarello CA, Kim SH: IL-32, a novel cytokine with a possible role in
disease. Ann Rheum Dis 2006, 65(Suppl 3):iii61-64.
18. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR,
Barrera P, van de Loo FA, Dinarello CA, van den Berg WB: IL-32, a
proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA
2006, 103:3298-3303.
19. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P:
Genome-wide comparison between IL-17A- and IL-17F-induced effects
in human rheumatoid arthritis synoviocytes. J Immunol 2009,
182:3112-3120.
20. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA,
Netea MG, van den Berg WB, Joosten LA: Tumour necrosis factor alpha-
driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies
an inflammatory cascade. Ann Rheum Dis 2011, 70:660-667.
21. Jung MY, Son MH, Kim SH, Cho D, Kim TS: IL-32gamma induces the
maturation of dendritic cells with Th1- and Th17-polarizing ability
through enhanced IL-12 and IL-6 production. J Immunol 2011,
186:6848-6859.
22. Turner-Brannen E, Choi KY, Arsenault R, El-Gabalawy H, Napper S,
Mookherjee N: Inflammatory cytokines IL-32 and IL-17 have common
signaling intermediates despite differential dependence on TNF-receptor
1. J Immunol 2011, 186:7127-7135.
23. Mabilleau G, Sabokbar A: Interleukin-32 promotes osteoclast
differentiation but not osteoclast activation. PLoS One 2009, 4:e4173.
24. Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B: Effect of interleukin-
32gamma on differentiation of osteoclasts from CD14+ monocytes.
Arthritis Rheum 2010, 62:515-523.
25. Astry B, Harberts E, Moudgil KD: A cytokine-centric view of the
pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine
Res 2011, 31:927-940.
26. McInnes IB, Leung BP, Liew FY: Cell-cell interactions in synovitis.
Interactions between T lymphocytes and synovial cells. Arthritis Res 2000,
2:374-378.
27. Alsaleh G, Sparsa L, Chatelus E, Ehlinger M, Gottenberg JE, Wachsmann D,
Sibilia J: Innate immunity triggers IL-32 expression by fibroblast-like
synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010, 12:R135.
28. Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y,
Yamamoto K: Interactions between IL-32 and tumor necrosis factor alpha
contribute to the exacerbation of immune-inflammatory diseases.
Arthritis Res Ther 2006, 8:R166.
29. Jeong HJ, Shin SY, Oh HA, Kim MH, Cho JS, Kim HM: IL-32 up-regulation is
associated with inflammatory cytokine production in allergic rhinitis.
J Pathol 2011, 224:553-563.
30. Yagi Y, Andoh A, Imaeda H, Aomatsu T, Ohsaki R, Inatomi O, Bamba S,
Tsujikawa T, Shimizu T, Fujiyama Y: Interleukin-32alpha expression in
human colonic subepithelial myofibroblasts. Int J Mol Med 2011,
27:263-268.
31. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, Kim do K, Kim HS,
Choi JD, Kim SH, Lee CK, Park SH, Kim BK, Kim HS, Kim YM, Choi WS: Tumor
necrosis factor alpha-induced interleukin-32 is positively regulated via
the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial
fibroblasts. Arthritis Rheum 2009, 60:678-685.
doi:10.1186/ar4089
Cite this article as: Moon et al.: IL-32 and IL-17 interact and have the
potential to aggravate osteoclastogenesis in rheumatoid arthritis.
Arthritis Research & Therapy 2012 14:R246.
Moon et al. Arthritis Research & Therapy 2012, 14:R246
http://arthritis-research.com/content/14/6/R246
Page 13 of 13
